Spheritech Revenue
Pharmaceutical Manufacturing • 
Runcorn, England, United Kingdom • 1-10 Employees
Spheritech revenue & valuation
| Annual revenue | $427,775 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $1,400,000 |
| Total funding | No funding |
Key Contact at Spheritech
Christopher Harris
Director
Company overview
| Headquarters | The Heath Business & Technical Park, Runcorn, Cheshire WA7 4QX, GB |
| Phone number | +441928511331 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Nanoparticles, Contact Lenses, 3D Cell Culture, Regenerative Medicine, Peptide Synthesis, Wound Management, Macroporous Polymers, Microparticles, Oligonucleotide Synthesis, Polymer Synthesis, Porous Polymers, Preparative Hplc |
| Founded | 2009 |
| Employees | 1-10 |
| Socials |
Spheritech Email Formats
Spheritech uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@spheritech.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@spheritech.com | 100% |
About Spheritech
SpheriTech, founded by Don Wellings in 2009 provides consultancy, synthesis, preparative HPLC, contract research and development to a range of industries. we have now installed a 15cm diameter NovaSep DAC, HPLC column. The company is internationally recognized authority on peptide synthesis, oligonucleotide synthesis, polymer particle design and chromatography. The founder is the author of numerous texts and book chapters and is the author of 'A Practical Handbook of Preparative HPLC'. With a track record for innovation he is the main inventor on 17 patents and the sole inventor on all patents filed by SpheriTech to-date. The company has a comprehensive range of equipment including HPLC systems from analytical through to preparative DAC based systems and specializes in contract purification of any molecule, be it small organic or complex protein. With decades of experience in biomolecule manufacture across the team Spheritech can perform complex solid phase synthesis of peptides and oligonucleotides in reactor volumes ranging from millilitres to multi-litre scale. The company has an extensive R&D program currently developing novel inexpensive technologies for the manufacture of polymer particles for applications in solid phase peptide and oligonucleotides synthesis, enzyme immobilization, affinity chromatography and transition metal catalysis. The R&D program also involves the development of novel macroporous polymer networks for cell culture with a particular focus on 3D stem cell culture and differentiation. The company is currently developing a new range of wound dressings based upon a proprietary biopolymer. The senior management team of SpheriTech has a total of 50 years of experience in cGMP manufacture and over 150 combined years’ experience in peptide synthesis. The Company provides consulting services related to process scale needs. SpheriTech also has a broad range of intellectual property covering a diverse platform of technologies.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Spheritech has never raised funding before.
Spheritech Tech Stack
Discover the technologies and tools that power Spheritech's digital infrastructure, from frameworks to analytics platforms.
Web servers
Font scripts
Security
JavaScript libraries
Form builders
Programming languages
Miscellaneous
Font scripts
Blogs
JavaScript libraries
Maps
Databases
France
United States
GermanyFrequently asked questions
4.8
40,000 users
